enGenes Biotech presents continuous plasmid DNA manufacturing at MSS2026 in Bled

Vienna, Austria: – Recombinant proteins and plasmid DNA specialist CDMO enGenes Biotech is heading to Bled, Slovenia, to present peer-reviewed data on continuous plasmid DNA (pDNA) manufacturing at the next-gen bioManufacturing & Delivery Science Symposium (MSS2026), running 14–16 September 2026 as a hybrid, onsite and online event.

Dr Juergen Mairhofer, CEO and co-founder of enGenes, will deliver a presentation in the symposium’s “Nucleic Acids and LNPs” stream, part of the “Next Generation Manufacturing Platforms” session, on Monday 14 September.

A single continuous line, from fermentation to purified plasmid

Dr Mairhofer’s talk, “iCAP: Integrated Continuous and Automated Platform for Plasmid Production”, runs from 16:10 to 17:00 in Hall F. It sets out how enGenes has combined a growth-decoupled E. coli host strain and fermentation process, inline alkaline lysis optimised with a mechanistic model, and monolithic chromatography into a single continuous line, monitored in real time.

Most plasmid DNA is still produced in batch mode, where yields are low and much of the eventual cost of goods is locked in as early as the fermentation step

Part of the dataset was developed with partners Sartorius BIA Separations, BOKU University Vienna, Novasign and Qubicon, and is published open access as Korn et al., Biochemical Engineering Journal 235 (2026) 110345.

To read more, click here: https://www.pharmaceutical-networking.com/engenes-biotech-presents-continuous-plasmid-dna-manufacturing-at-mss2026-in-bled/